OLEMA PHARMACEUTICALS INC. - COMMON STOCK

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

22 10 2023 02:55:00 提供 Nasdaq GlobeNewswire

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

17 10 2023 07:01:00 提供 Nasdaq GlobeNewswire

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

16 10 2023 07:02:00 提供 Nasdaq GlobeNewswire

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

12 10 2023 07:01:00 提供 Nasdaq GlobeNewswire

Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

10 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 10 2023 16:30:00 提供 Nasdaq GlobeNewswire

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

20 9 2023 07:29:20 提供 Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

06 9 2023 16:30:55 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 9 2023 16:30:00 提供 Nasdaq GlobeNewswire

Olema Oncology Announces Combined Financing for Up to $180 Million

05 9 2023 07:30:49 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

08 8 2023 16:03:07 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 8 2023 16:30:34 提供 Nasdaq GlobeNewswire

Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference

01 8 2023 08:00:10 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 7 2023 07:30:32 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 6 2023 16:30:23 提供 Nasdaq GlobeNewswire

Olema Oncology to Present at the 2023 Jefferies Healthcare Conference

30 5 2023 16:30:43 提供 Nasdaq GlobeNewswire

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

11 5 2023 08:43:20 提供 Nasdaq GlobeNewswire

Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update

09 5 2023 16:01:03 提供 Nasdaq GlobeNewswire

Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress

08 5 2023 07:06:10 提供 Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 5 2023 16:30:57 提供 Nasdaq GlobeNewswire